Protalix Biotherapeutics, Inc. (PLX)

3.105 +0.04 (+1.47%) USD  |  NYAM  |  Feb 23, 11:34
More

Protalix Biotherapeutics SG&A Expense (Quarterly) : 2.929M for Sept. 30, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for PLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Denali Therapeutics, Inc. 35.48M
OraSure Technologies, Inc. 17.38M
Nephros, Inc. 2.229M
Agenus, Inc. 10.86M
Curis, Inc. 3.653M